{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T01:25:37Z","timestamp":1789435537538,"version":"build-2803163510"},"reference-count":50,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,7]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>Patients with chronic kidney disease have a high risk of fractures and no established treatments that have been shown to prevent the bone disease. The physiology of renal osteodystrophy is complex and recently more factors have been found that complicate the mineral metabolism. The recognition that vascular calcifications are related to bone disease has made treatment even more challenging.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>The most exciting new findings relate to the signaling pathways that are seen in kidney disease and how they cause abnormalities in bone physiology. In particular, wnt and activin signaling pathways are seen early in the course of renal disease. The bones react by increasing FGF-23, which targets both renal phosphate secretion and a variety of other systemic effects. Secreted klotho is another newly described hormone with effects on several systems.<\/jats:p>\n            <jats:p>Clinical studies have focused on treatments for hyperparathyroidism and phosphate, and frustrating limitations of the treatments used for ordinary osteoporosis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>Treatment of bone disease in patients with chronic kidney disease is challenging, and understanding the physiological pathways could lead to novel therapies.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/bor.0000000000000626","type":"journal-article","created":{"date-parts":[[2019,5,25]],"date-time":"2019-05-25T03:15:59Z","timestamp":1558754159000},"page":"394-399","source":"Crossref","is-referenced-by-count":4,"title":["Renal insufficiency and bone loss"],"prefix":"10.1097","volume":"31","author":[{"given":"Susan M.","family":"Ott","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230829","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1002\/jbmr.403","article-title":"Effects of denosumab on fracture and bone mineral density by level of kidney function","volume":"26","author":"Jamal","year":"2011","journal-title":"J Bone Miner Res"},{"key":"R2-20230829","doi-asserted-by":"crossref","DOI":"10.1002\/jbmr.3676","article-title":"Effects of denosumab and alendronate on bone health and vascular function in hemodialysis patients: a randomized, controlled trial","author":"Iseri","year":"2019","journal-title":"J Bone Miner Res"},{"key":"R3-20230829","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1111\/imj.13744","article-title":"Acute hypocalcaemia following denosumab in heart and lung transplant patients with osteoporosis","volume":"48","author":"Shrosbree","year":"2018","journal-title":"Intern Med J"},{"key":"R4-20230829","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.amjms.2017.09.008","article-title":"Denosumab-associated severe hypocalcemia in a patient with chronic kidney disease","volume":"355","author":"Salim","year":"2018","journal-title":"Am J Med Sci"},{"key":"R5-20230829","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s40620-016-0334-1","article-title":"Safety and efficacy of denosumab in osteoporotic hemodialysed patients","volume":"30","author":"Festuccia","year":"2017","journal-title":"J Nephrol"},{"key":"R6-20230829","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1177\/1078155216628325","article-title":"Incidence of hypocalcemia in patients receiving denosumab for prevention of skeletal-related events in bone metastasis","volume":"23","author":"Yerram","year":"2017","journal-title":"J Oncol Pharm Pract"},{"key":"R7-20230829","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.nefro.2016.02.007","article-title":"Severe hypocalcemia following denosumab injection in patient with chronic kidney disease","volume":"34","author":"Monge Rafael","year":"2016","journal-title":"Nefrologia"},{"key":"R8-20230829","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1111\/nep.12432","article-title":"Hypocalcaemic tetany occurring post a single denosumab dose in a patient with stage 4 chronic kidney disease, followed by calcium- and calcitriol-induced hypercalcaemia","volume":"20","author":"Lambe","year":"2015","journal-title":"Nephrology (Carlton)"},{"key":"R9-20230829","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1053\/j.ajkd.2015.03.012","article-title":"Denosumab for low bone mass in hemodialysis patients: a noncontrolled trial","volume":"66","author":"Hiramatsu","year":"2015","journal-title":"Am J Kidney Dis"},{"key":"R10-20230829","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1159\/000380960","article-title":"Hypocalcemia post denosumab in patients with chronic kidney disease stage 4-5","volume":"41","author":"Dave","year":"2015","journal-title":"Am J Nephrol"},{"key":"R11-20230829","first-page":"542","article-title":"Extreme hypocalcaemia and hyperparathyroidism following denosumab. Is this drug safe in chronic kidney disease?","volume":"34","author":"Sirvent","year":"2014","journal-title":"Nefrologia"},{"key":"R12-20230829","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.2169\/internalmedicine.54.4946","article-title":"Rapid progression of vascular and soft tissue calcification while being managed for severe and persistent hypocalcemia induced by denosumab treatment in a patient with multiple myeloma and chronic kidney disease","volume":"54","author":"Ueki","year":"2015","journal-title":"Intern Med"},{"key":"R13-20230829","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1007\/s00198-018-4589-3","article-title":"Skeletal accumulation of fluorescently tagged zoledronate is higher in animals with early stage chronic kidney disease","volume":"29","author":"Swallow","year":"2018","journal-title":"Osteoporos Int"},{"key":"R14-20230829","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1002\/jbmr.2702","article-title":"Adynamic bone decreases bone toughness during aging by affecting mineral and matrix","volume":"31","author":"Ng","year":"2016","journal-title":"J Bone Miner Res"},{"key":"R15-20230829","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.kint.2018.10.010","article-title":"Emerging role of myostatin and its inhibition in the setting of chronic kidney disease","volume":"95","author":"Verzola","year":"2019","journal-title":"Kidney Int"},{"key":"R16-20230829","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1152\/physrev.00002.2018","article-title":"Activin A in mammalian physiology","volume":"99","author":"Bloise","year":"2019","journal-title":"Physiol Rev"},{"key":"R17-20230829","doi-asserted-by":"crossref","first-page":"222","DOI":"10.5414\/CN109650","article-title":"Serum bone markers in ROD patients across the spectrum of decreases in GFR: activin A increases before all other markers","volume":"91","author":"Lima","year":"2019","journal-title":"Clin Nephrol"},{"key":"R18-20230829","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.kint.2017.06.016","article-title":"The activin receptor is stimulated in the skeleton, vasculature, heart, and kidney during chronic kidney disease","volume":"93","author":"Williams","year":"2018","journal-title":"Kidney Int"},{"key":"R19-20230829","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.kint.2016.07.039","article-title":"Ligand trap of the activin receptor type IIA inhibits osteoclast stimulation of bone remodeling in diabetic mice with chronic kidney disease","volume":"91","author":"Sugatani","year":"2017","journal-title":"Kidney Int"},{"key":"R20-20230829","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/j.kint.2016.02.002","article-title":"Ligand trap for the activin type IIA receptor protects against vascular disease and renal fibrosis in mice with chronic kidney disease","volume":"89","author":"Agapova","year":"2016","journal-title":"Kidney Int"},{"key":"R21-20230829","article-title":"ACVR1-knockout promotes osteogenic differentiation by activating the Wnt signaling pathway in mice","author":"Wang","year":"2018","journal-title":"J Cell Biochem"},{"key":"R22-20230829","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1002\/jbmr.2372","article-title":"Anti-sclerostin antibody treatment in a rat model of progressive renal osteodystrophy","volume":"30","author":"Moe","year":"2015","journal-title":"J Bone Miner Res"},{"key":"R23-20230829","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/nyas.13945","article-title":"Wnt signaling in bone, kidney, intestine, and adipose tissue and interorgan interaction in aging","volume":"1442","author":"Chen","year":"2019","journal-title":"Ann N Y Acad Sci"},{"key":"R24-20230829","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/j.kint.2018.10.032","article-title":"Wnt\/beta-catenin links oxidative stress to podocyte injury and proteinuria","volume":"95","author":"Zhou","year":"2019","journal-title":"Kidney Int"},{"key":"R25-20230829","doi-asserted-by":"crossref","DOI":"10.1016\/j.kint.2018.12.024","article-title":"Bone mineral density, bone turnover markers, and incident fractures in de novo kidney transplant recipients","author":"Evenepoel","year":"2019","journal-title":"Kidney Int"},{"key":"R26-20230829","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1002\/jbmr.3562","article-title":"Chronic kidney disease is associated with greater bone marrow adiposity","volume":"33","author":"Woods","year":"2018","journal-title":"J Bone Miner Res"},{"key":"R27-20230829","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s00198-017-4228-4","article-title":"Two-year cortical and trabecular bone loss in CKD-5D: biochemical and clinical predictors","volume":"29","author":"Malluche","year":"2018","journal-title":"Osteoporos Int"},{"key":"R28-20230829","doi-asserted-by":"crossref","first-page":"18","DOI":"10.5414\/CN109333","article-title":"Sclerostin is not associated with cardiovascular event or fracture in kidney transplantation candidates","volume":"90","author":"Jorgensen","year":"2018","journal-title":"Clin Nephrol"},{"key":"R29-20230829","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.bone.2017.11.015","article-title":"Sclerostin deficiency modifies the development of CKD-MBD in mice","volume":"107","author":"Kaesler","year":"2018","journal-title":"Bone"},{"key":"R30-20230829","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1007\/s11914-018-0486-0","article-title":"CKD-MBD: from the pathogenesis to the identification and development of potential novel therapeutic targets","volume":"16","author":"Elias","year":"2018","journal-title":"Curr Osteoporos Rep"},{"key":"R31-20230829","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1097\/MNH.0000000000000467","article-title":"Fibroblast growth factor 23 and alpha-Klotho co-dependent and independent functions","volume":"28","author":"Quarles","year":"2019","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"R32-20230829","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1016\/j.kint.2017.11.018","article-title":"Erythropoietin induces bone marrow and plasma fibroblast growth factor 23 during acute kidney injury","volume":"93","author":"Toro","year":"2018","journal-title":"Kidney Int"},{"key":"R33-20230829","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.2215\/CJN.03270314","article-title":"Effect of cinacalcet and vitamin D analogs on fibroblast growth factor-23 during the treatment of secondary hyperparathyroidism","volume":"10","author":"Sprague","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"key":"R34-20230829","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.kint.2016.01.024","article-title":"Direct inhibition of osteoblastic Wnt pathway by fibroblast growth factor 23 contributes to bone loss in chronic kidney disease","volume":"90","author":"Carrillo-Lopez","year":"2016","journal-title":"Kidney Int"},{"key":"R35-20230829","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1007\/s00198-018-4598-2","article-title":"FGF23-klotho axis, bone fractures, and arterial stiffness in dialysis: a case-control study","volume":"29","author":"Desbiens","year":"2018","journal-title":"Osteoporos Int"},{"key":"R36-20230829","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s00424-018-2238-5","article-title":"Role of alphaKlotho and FGF23 in regulation of type II Na-dependent phosphate co-transporters","volume":"471","author":"Hu","year":"2019","journal-title":"Pflugers Arch"},{"key":"R37-20230829","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1097\/MNH.0000000000000415","article-title":"alpha-Klotho's effects on mineral homeostasis are fibroblast growth factor-23 dependent","volume":"27","author":"Erben","year":"2018","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"R38-20230829","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1097\/MNH.0000000000000423","article-title":"Role of Klotho in bone and implication for CKD","volume":"27","author":"Komaba","year":"2018","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"R39-20230829","doi-asserted-by":"crossref","DOI":"10.1002\/ejhf.1424","article-title":"Klotho, fibroblast growth factor-23, and the renin-angiotensin system - an analysis from the PEACE trial","author":"Bergmark","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"R40-20230829","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s12882-018-0851-3","article-title":"The association between soluble klotho and cardiovascular parameters in chronic kidney disease: results from the KNOW-CKD study","volume":"19","author":"Kim","year":"2018","journal-title":"BMC Nephrol"},{"key":"R41-20230829","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1159\/000496060","article-title":"Fibroblast growth factor 23 genotype and cardiovascular disease in patients undergoing hemodialysis","volume":"49","author":"Schwantes-An","year":"2019","journal-title":"Am J Nephrol"},{"key":"R42-20230829","doi-asserted-by":"crossref","DOI":"10.1093\/ndt\/gfy392","article-title":"Fibroblast growth factor-23 promotes rhythm alterations and contractile dysfunction in adult ventricular cardiomyocytes","author":"Navarro-Garcia","year":"2019","journal-title":"Nephrol Dial Transplant"},{"key":"R43-20230829","doi-asserted-by":"crossref","first-page":"693","DOI":"10.2217\/cer-2018-0015","article-title":"Effects of calcimimetics on long-term outcomes in dialysis patients: literature review and Bayesian meta-analysis","volume":"7","author":"Lozano-Ortega","year":"2018","journal-title":"J Comp Eff Res"},{"key":"R44-20230829","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1038\/s41598-018-20552-5","article-title":"Cinacalcet use and the risk of cardiovascular events, fractures and mortality in chronic kidney disease patients with secondary hyperparathyroidism","volume":"8","author":"Evans","year":"2018","journal-title":"Sci Rep"},{"key":"R45-20230829","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/j.kint.2018.05.013","article-title":"Head-to-head comparison of the new calcimimetic agent evocalcet with cinacalcet in Japanese hemodialysis patients with secondary hyperparathyroidism","volume":"94","author":"Fukagawa","year":"2018","journal-title":"Kidney Int"},{"key":"R46-20230829","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1001\/jama.2016.19468","article-title":"Effect of etelcalcetide vs cinacalcet on serum parathyroid hormone in patients receiving hemodialysis with secondary hyperparathyroidism: a randomized clinical trial","volume":"317","author":"Block","year":"2017","journal-title":"JAMA"},{"key":"R47-20230829","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.2147\/DDDT.S134103","article-title":"Role of etelcalcetide in the management of secondary hyperparathyroidism in hemodialysis patients: a review on current data and place in therapy","volume":"12","author":"Friedl","year":"2018","journal-title":"Drug Des Devel Ther"},{"key":"R48-20230829","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/sdi.12710","article-title":"Current and potential therapeutic strategies for the management of vascular calcification in patients with chronic kidney disease including those on dialysis","volume":"31","author":"Ruderman","year":"2018","journal-title":"Semin Dial"},{"key":"R49-20230829","first-page":"CD006023","article-title":"Phosphate binders for preventing and treating chronic kidney disease-mineral and bone disorder (CKD-MBD)","volume":"8","author":"Ruospo","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"R50-20230829","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1681\/ASN.2015030268","article-title":"Reduction of dialysate calcium level reduces progression of coronary artery calcification and improves low bone turnover in patients on hemodialysis","volume":"27","author":"Ok","year":"2016","journal-title":"J Am Soc Nephrol"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00002281-201907000-00013","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T06:41:25Z","timestamp":1693291285000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00002281-201907000-00013"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":50,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0000000000000626","relation":{},"ISSN":["1040-8711","1531-6963"],"issn-type":[{"value":"1040-8711","type":"print"},{"value":"1531-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7]]}}}